SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?


To: Mark Konrad who wrote (29163)7/8/2000 2:54:33 PM
From: johnsto1  Read Replies (1) | Respond to of 57584
 
Mark,glad to bring winners to Randes place,I have done well following you all before I figured some things out.

A brief synopsis of where the "money" is coming from for these focused Genomic companies(PBSC,LEXG,ORCH,GNSL):
-Deciphering the function of genes and developing tools to help pharmaceutical companies use genes as medicine...pharmaceudicals have literally billions to spend to these companies for these answers

-the genomics revolution is a world event and these new leaders are attracting a large pool of world fund buying. The car is just leaving the driveway.

Personally I think ORCH is the Gorilla in the making with it's patents in SNP'S technolgy(personalized medicine);
but all are exciting and PBSC is a real sleeper. LEXG ready for another burst soon.



To: Mark Konrad who wrote (29163)7/8/2000 4:07:14 PM
From: johnsto1  Read Replies (1) | Respond to of 57584
 
ORCH ceo articulates pharmaceuticals need for genomics products
July 7, 2000

--------------------------------------------------------------------------------

Orchid BioSciences To Generate Value In Mid-Term - CEO
Dow Jones Newswires

NEW YORK -- Orchid BioSciences Inc. (ORCH) is building a foundation to generate value in the mid- to long term, the company's chairman and chief executive said Friday.

Dale Pfost told CNBC that the company, which produces kits to measure genetic diversity and hasn't made any profit yet, is operating in an "explosively growing marketplace."

"The pharmaceutical and agriculture industries are already using our technology" to develop specific drugs or treatments, he said.

Besides, he said, "our competitors are potential partners, because our technology can work inside their instrumentation."

Orchid chip-based technology is already successfully applied in the treatment of leukemia, Pfost added, to tailor medications to the individual patient.

Pfost predicted a strong demand for his company's technology. "The pharmaceutical industry needs to find a plurality of drugs that work for the population at large," he said. "They need a test to define which drug to use with which patient, and this is the technology that we have."

-Elena Molinari, Dow Jones Newswires; 201-938-2312



To: Mark Konrad who wrote (29163)7/8/2000 5:12:50 PM
From: Mark Konrad  Read Replies (4) | Respond to of 57584
 
Quickie TA/chart analysis for some selected stocks I own or am tracking. For purposes here, fundamentals are either ignored or are presumed to be reflected by current price and movement (all data from market close 7/6/00). These are my opinions only, fwiw, so do your own dd! Responses and comments from any and all would be greatly appreciated!

Stocks that have given new or recent "position buy" signals (NOT daytrades) based upon bullish chart formations and conservative slow-moving stochastics (from Askresearch.com):
GBLX, ANAD, HLTH, COVD, OMKT, CICI, PSFT, AOL, NXTL, JNIC, CSCO, WFII, ARTT, NOK, MOT, CTXS, AMD, INTC, IBM (holding support in 100-105 area), EGAN, DISH (a close above 38 would break declining tops line and be very significant). Additionally, I have a "buy" on "QQQ" which may be a prudent way to play the biggest on the NAZ for most investors (provides some "landmine" protection!).

Recent breakouts:
ADAP (made breakout at 35), NTRO (held support at 48, made breakout at 55), MSFT (strong buy at 65, latest breakout will be at 83), WCOM (strong buy at 40, made breakout at 45), NT (strong buy at 55, latest breakout will be at 73), Q (made breakout at 54), FNSR (strong buy at 22, met my target of 30, must break strongly above 30 to continue run), SCMR (held trendline, made breakout at 121), CS (buy at 22, watch for breakout above 27), RSAS (I keep forgetting this one as it is only in my LT portfolio but the strong buys were at 45 and 55 with a recent breakout at 65; if I didn't have it, I'd buy some here and tuck it away).

Tech fliers currently in short term downtrends (holds or sells depending upon personal preferences and fundamentals not readily available or factored into prices):
AETH, JDSU, GLW, LPTHA, SCON, ISLD, ADIC, XYBR, DITC, CNXT (held trendline at 46 so I'm watching closely for a possible buy Monday or Tuesday), LU (also watching closely for buy), ATHM (trendline support at 18 1/2 so this may be a buy), QCOM (how low is "low" for this giant?), EXDS (however I just bought some at 41), ELON (although I may buy this one soon, too), SBAS (breakout was at 6 1/2, I sold at 10, now waiting for new buy), VTSS (may have bottomed already along with AMD and other semis), "A" (Agilent) is in a downtrend but could reverse very quickly especially if it holds support above 66 (I bought the other day at 68).

Sleeping with the fishes (but could wake up!): Note, the first three were fiascos for me and wiped out lots of hard-earned profits--diversification is a MUST!
IONN, NBCI, HLIT, ENGA, HEAR, IFMX, NATS, IAAC, JMAR, PNLK, USTI.

All of the above are only my opinions and the list is not complete by any means. Biotechs were left out as I own only a few and some are recent IPO's. I also have no interest in cyclicals, consumer staples, REITs, etc.

Looking forward to hearing back from Rande and the Thread!

Very best regards, Mark